FONT-SIZE Plus   Neg

Novartis' Lung Disease Drug QVA149 Meet Primary Endpoints In Phase III Studies

Swiss pharmaceutical giant Novartis AG (NVS) on Monday said its first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease or COPD all met their primary endpoints.

QVA149, a bronchodilator with dual mode of action, is Novartis' third innovation in its Breezhaler single dose dry powder inhaler.

According to the company, the SHINE, BRIGHT and ENLIGHTEN studies demonstrate the potential of QVA149 in the treatment of COPD. The studies are components of the IGNITE Phase III clinical trial program intended to form the basis for an NDA filing in COPD.

The results of SHINE met the primary endpoint by demonstrating the superiority in trough FEV of once-daily QVA149 compared to once-daily indacaterol or once-daily NVA237 in patients with moderate to severe COPD.

The results of BRIGHT demonstrated that patients experienced significantly better exercise endurance versus placebo and ENLIGHTEN showed that QVA149 was well tolerated with a safety and tolerability profile similar to placebo.

Tim Wright, Head of Development, Novartis Pharmaceuticals, said, "Meeting the primary endpoints in the IGNITE Phase III clinical trial program signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio."

The company noted that the data from the IGNITE clinical trial program examining QVA149 in a number of settings will be submitted for presentation to a major medical congress later this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks is rolling out its delivery service - good news for any caffeine addicts who can't make it out to the coffee chain. Unfortunately, there's still a wait in store for most people: the new service only covers Manhattan's most recognizable skyscraper. According to multiple media reports, Starbucks' pilot program is launching at the Empire State Building in New York City. Tech giant Apple Inc. Tuesday said the 21.5 inch iMac all-in-one desktop computers will be available with new Retina 4K display, while every 27 inch iMac will have Retina 5k display for true to life pictures and videos. The new iMacs will be supported by processors and graphics, two Thunderbolt 2 ports and new storage options. Popular sports news websites Deadspin and SBNation had their Twitter feeds suspended on Monday for alleged copyright violations. According to various media reports, Twitter halted @Deadspin and @SBNationGIF after the social media giant received complaints from various sources, including the NFL, the UFC and a couple of college football conferences.
comments powered by Disqus
Follow RTT